User:Mr. Ibrahem/Fesoterodine

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Fesoterodine
Space-filling model of the fesoterodine molecule
Clinical data
Trade namesToviaz, others
AHFS/Drugs.comMonograph
MedlinePlusa609021
License data
Routes of
administration
By mouth
Drug classAntimuscarinic[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability52% (active metabolite)
Protein binding50% (active metabolite)
MetabolismLiver (CYP2D6- and 3A4-mediated)
Elimination half-life7–8 hours (active metabolite)
ExcretionKidney (70%) and fecal (7%)
Identifiers
  • [2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
Chemical and physical data
FormulaC26H37NO3
Molar mass411.586 g·mol−1
3D model (JSmol)
  • O=C(Oc1ccc(cc1[C@@H](c2ccccc2)CCN(C(C)C)C(C)C)CO)C(C)C
  • InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1 checkY
  • Key:DCCSDBARQIPTGU-HSZRJFAPSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Fesoterodine, sold under the brand name Toviaz among others, is a medication used to treat the symptoms of overactive bladder syndrome (OAB).[1][3] It is a second line medication for this use.[4] It is taken by mouth.[1]

Common side effects include dry mouth and constipation.[1] Other side effects may include urinary retention, trouble sleeping, and dizziness.[1][4] It is not recommended in people with severe liver problems or myasthenia gravis.[3] It is an antimuscarinic and works via the same chemical as tolterodine.[1]

Fesoterodine was approved for medical use in Europe in 2007,[3] the United States in 2008,[1] and Canada in 2012.[5] In the United States it costs about 310 USD per month as of 2021.[6] This amount in the United Kingdom costs the NHS about £26.[4]

References[edit]

  1. ^ a b c d e f g h i j "Fesoterodine Monograph for Professionals". Drugs.com. Archived from the original on 26 January 2021. Retrieved 23 July 2021.
  2. ^ "Fesoterodine (Toviaz) Use During Pregnancy". Drugs.com. 7 November 2019. Archived from the original on 29 November 2020. Retrieved 12 August 2020.
  3. ^ a b c "Toviaz". Archived from the original on 12 November 2020. Retrieved 4 August 2021.
  4. ^ a b c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 821. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  5. ^ "Notice of Decision for TOVIAZ". Archived from the original on 2012-04-23. Retrieved 2012-04-20.
  6. ^ "Toviaz Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 4 August 2021.